NC-6300: Ph I data

An open-label, Japanese Phase I trial in 19 patients with advanced or recurrent malignant solid tumors either refractory to standard therapy or for whom no other viable treatments options were available showed that 15-225 mg/m² doses of IV NC-6300 every 3 weeks led to 1 partial response and 10 cases of stable disease. NC-6300 was well tolerated. The MTD and recommended Phase II dose was 170 mg/m² NC-6300 every 3 weeks. Data were published in Investigational New Drugs...